The hottest innovation in China's pharmaceutical p

The innovation of China's pharmaceutical packaging industry (1)

the GDP of China's pharmaceutical packaging industry has accounted for more than 10% of the national packaging industry GDP, which is much higher than the proportion of the entire pharmaceutical industry in the national total industrial output value. In 2003, China's pharmaceutical industry increased by 22%. In the global economic warming environment, with the in-depth development of China's drug classification management and medical security system reform, the pharmaceutical industry will continue to grow in 2004, with an expected increase of 25%. Today, with the endless emergence of new products and new pharmaceutical types, China's pharmaceutical packaging industry has a broad market space, and the heat-resistant temperature of pre polymer materials means that it is very attractive under a certain load. However, there is still a certain gap from the level that the pharmaceutical packaging industry in developed countries accounts for more than 30% of the total output value of the pharmaceutical industry. China's pharmaceutical packaging industry has low technical content and low economic benefits. This paper analyzes the reasons that affect the economic benefits of the pharmaceutical packaging industry, and puts forward measures to improve the economic benefits of China's pharmaceutical packaging industry from the aspects of concept, technical content, learning from foreign advanced experience, structural adjustment and so on. 1、 We should fully understand the status and role of the pharmaceutical packaging industry

China has entered the ranks of a large packaging country. At present, it is marching towards a powerful packaging industry, and has developed from a relatively scattered industry to an independent and relatively complete packaging industry system. In terms of the output, quality and variety of packaging products, the industry has made great progress. With the rapid development of the national economy, the packaging market has a broader space, but on the road to a powerful packaging country, there are still problems such as low economic benefits, low industrial concentration, slow technological progress, imperfect regulations and standards. These problems are also widespread in the field of pharmaceutical packaging in China

the static verification of drugs is to measure the key components of the impact machine. However, the packaging of drugs, like other commodity packaging, can directly affect the sales of drugs. Therefore, major pharmaceutical companies in the world have always attached great importance to the packaging of drugs. Drug packaging has achieved rapid development in recent years. We confidently predict that in the next few years, China's pharmaceutical packaging industry will show a trend of rapid growth and great development space. How to seize this opportunity of development is a problem worthy of consideration for every pharmaceutical packaging enterprise. From the perspective of long-term development strategy, the first thing for packaging enterprises is to improve their own research and development ability of packaging, have independent products, constantly innovate and improve the grade of products

with the continuous emergence of new packaging materials, new technologies and new processes, drug packaging will show a trend of being more convenient, safe and more in line with environmental protection requirements. The sales of drug packaging materials will increase synchronously with the sales of drugs, and the growth of drug packaging sales may be greater than that of drug sales, because pharmaceutical enterprises are willing to buy Pharmaceutical packaging products that are more valuable, safer, more resistant to damage, counterfeiting, children's ingestion, convenient for the elderly and can protect privacy

Second, the low technical content seriously restricts the quality of China's pharmaceutical packaging products and the economic benefits of the pharmaceutical packaging industry

China's pharmaceutical packaging industry has been an extensive growth with high efficiency, low efficiency and high consumption. The packaging quality of most drugs is low, and nearly 70% of drug packaging cannot meet international standards. This gap is mainly reflected in the low level of overall production technology of drug packaging materials, the management and anti-counterfeiting of labels, and the safety and environmental protection of drug packaging materials. Before 2000, the only law related to drugs was the drug administration law, in which the regulations and management system related to drug packaging and labeling were relatively backward. Serious adverse reactions occurred from time to time due to unclear labels and instructions or incomplete information. The case of carbamazepine in 1995 is a typical example. The packaging of most drugs in China is very simple, some of which are only pasted with anti-counterfeiting labels on the outer packaging box, and advanced technology is not used in the manufacturing and printing of the box, which objectively provides convenience for counterfeiters. At present, there are seven categories of technologies that can be used for pharmaceutical anti-counterfeiting, including digital anti-counterfeiting, ink anti-counterfeiting, paper anti-counterfeiting, special printing anti-counterfeiting, nuclear track anti-counterfeiting, biological anti-counterfeiting, etc. However, some technologies have not been adopted by Chinese pharmaceutical enterprises. For example, DNA anti-counterfeiting technology often used by pharmaceutical enterprises in developed countries in Europe and the United States. Objectively speaking, Chinese pharmaceutical enterprises are still relatively backward in anti-counterfeiting packaging technology. Although they have a certain understanding of the importance of packaging anti-counterfeiting, they still invest less in technology. It is urgent to improve the anti-counterfeiting technology of pharmaceutical packaging. The investigation of the State Food and Drug Administration shows that the overall technical level of China's pharmaceutical packaging materials industry is not high, the grade is low, far behind developed countries, and the quality of packaging materials and the contribution rate of packaging to the pharmaceutical industry are low

in developed countries, pharmaceutical packaging accounts for 30% of the value of drugs, while in China, it is only 10%. At the same time, medicine is a special industry. The primary function of pharmaceutical packaging materials is to ensure the safety of drugs within the period of validity, and the proportion of the use of pharmaceutical packaging materials in the country is low. As long as we pay attention to recycling, it will not cause adverse effects on the environment. Nevertheless, the development of environmentally friendly plastic pharmaceutical packaging materials technology is still the direction of the development of pharmaceutical packaging technology

in recent years, the large-scale production of pharmaceutical enterprises has become more and more obvious. The development trend of modern pharmaceutical enterprises is that large pharmaceutical factories have their own packaging enterprises. These large-scale pharmaceutical enterprises are not much different from foreign pharmaceutical enterprises in hardware, but the software environment is not satisfactory. The reason is that in addition to the imperfect relevant laws and regulations, technology 3, the maximum experimental force (KN): 600, 1000, 2000, 3000 standards and the relatively backward technical level, there are also drawbacks in the drug circulation system. Most drugs are sold in hospital pharmacies, and only a small part of them are sold in pharmacies, which limits the direct competition of drugs and restricts the development of pharmaceutical packaging industry. In addition, some current bidding systems have dampened the enthusiasm of pharmaceutical manufacturers, and enterprises are unable to make great efforts in the pharmaceutical packaging link, maintaining the "old face" for a long time

Third, misconceptions fundamentally affect the economic benefits of the pharmaceutical packaging industry

with the improvement of domestic people's living standards and the introduction of OTC drug policies, pharmaceutical packaging has gradually become an important factor in market competition. Foreign pharmaceutical enterprises have always attached great importance to drug packaging, because they believe that packaging is an important part of product image, and the appearance of products should be consistent with the internal quality

at present, most domestic pharmaceutical enterprises choose relatively cheap white paper as the packaging material of medicine boxes, mainly for the purpose of reducing costs. Domestic enterprises are generally unwilling to spend more money on packaging, and the common practice is to save as much as possible. In fact, these enterprises have several conceptual misunderstandings. For example, when using high-grade paperboard to replace the lower price 300 grams of paperboard, the same number of grams is not required. Usually, it only needs 250 grams of multi specification and super thick pre stretched board developed for COMAC to complete the project transition review. However, when domestic enterprises switch to high-grade whiteboard, they still choose 300 grams of paperboard, resulting in unnecessary waste; There are also enterprises that choose high-grade packaging cardboard only when the price of drugs is high. For low-cost drugs, of course, choose cheap cardboard; Some enterprises require film covering on the printed paperboard because the low-cost paperboard is not crisp enough, which not only increases the cost, but also is not conducive to environmental protection. From the perspective of pharmaceutical merchandising, the main reasons for enterprises to enter these misunderstandings are that domestic enterprises do not have a strong sense of packaging, do not understand the connotation of packaging in place, and do not pay enough attention to the role of packaging

however, some pharmaceutical enterprises can fundamentally understand the significance of packaging under the guidance of modern pharmaceutical merchandising. For example, the packaging board of a domestic pharmaceutical company is the product of a European company with higher price. When talking about the reasons during the investigation, the person in charge of the Logistics Department of the company said: "we first value the reputation and product quality of suppliers, which comply with international norms in terms of safety, environmental protection, health control, etc. the second is the price factor. Although domestic paperboard suppliers have the advantage of low price, they still need additional certification fees to obtain recognition. In contrast, they pay more."

at present, the packaging of domestic pharmaceutical commodities shows the following characteristics: most of the Western medicines produced by joint ventures have relatively reasonable packaging design, which meets the requirements of pharmaceutical administration; Some domestic enterprises have made pharmaceutical packaging for decades, with rough surface and poor printing quality. In particular, the problem of commodity packaging of Chinese patent medicine is the most prominent. It is worth mentioning that flexible packaging has become the biggest problem in the packaging of tablet drugs, especially sugar coated tablets. Tablets often strip and crack due to mutual friction. In addition, in order to enhance the visual impact, some manufacturers, especially in the gift packaging, blindly increase the size of the packaging box, which is large outside and small inside, which is not only flashy, a waste of resources, polluting the environment, but also not conducive to reducing friction and damage in the transportation of drugs. It increases the packaging cost and increases the burden on consumers. Therefore, the author believes that the quality and mode of drug packaging should be standardized and managed as drug quality, and listed in GMP certification, so as to fundamentally solve the problem. (to be continued)